Atara Biotherapeutics, Inc. (ATRA): Price and Financial Metrics
ATRA Price/Volume Stats
| Current price | $1.54 | 52-week high | $9.34 |
| Prev. close | $1.50 | 52-week low | $1.45 |
| Day low | $1.46 | Volume | 2,211,900 |
| Day high | $1.57 | Avg. volume | 1,349,397 |
| 50-day MA | $2.52 | Dividend yield | N/A |
| 200-day MA | $3.71 | Market Cap | 150.88M |
ATRA Stock Price Chart Interactive Chart >
ATRA POWR Grades
- Value is the dimension where ATRA ranks best; there it ranks ahead of 63.03% of US stocks.
- The strongest trend for ATRA is in Sentiment, which has been heading down over the past 179 days.
- ATRA's current lowest rank is in the Sentiment metric (where it is better than 1.05% of US stocks).
ATRA Stock Summary
- Of note is the ratio of ATARA BIOTHERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.17% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 392.92%, ATARA BIOTHERAPEUTICS INC's debt growth rate surpasses 96.12% of about US stocks.
- Revenue growth over the past 12 months for ATARA BIOTHERAPEUTICS INC comes in at 138.51%, a number that bests 95.43% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ATARA BIOTHERAPEUTICS INC, a group of peers worth examining would be RNA, INVZ, FATE, ARVN, and AFMD.
- ATRA's SEC filings can be seen here. And to visit ATARA BIOTHERAPEUTICS INC's official web site, go to www.atarabio.com.
ATRA Valuation Summary
- ATRA's EV/EBIT ratio is -1.1; this is 109.17% lower than that of the median Healthcare stock.
- ATRA's price/sales ratio has moved NA NA over the prior 105 months.
Below are key valuation metrics over time for ATRA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ATRA | 2023-05-23 | 3.5 | 3.1 | -0.9 | -1.1 |
| ATRA | 2023-05-22 | 3.6 | 3.2 | -1.0 | -1.1 |
| ATRA | 2023-05-19 | 3.6 | 3.2 | -1.0 | -1.1 |
| ATRA | 2023-05-18 | 3.5 | 3.1 | -0.9 | -1.1 |
| ATRA | 2023-05-17 | 3.5 | 3.1 | -0.9 | -1.1 |
| ATRA | 2023-05-16 | 3.5 | 3.1 | -0.9 | -1.1 |
ATRA Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 12.41%.
- Its 3 year net income to common stockholders growth rate is now at -36.94%.
- Its year over year net income to common stockholders growth rate is now at -12.35%.
The table below shows ATRA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 63.573 | -270.43 | -228.302 |
| 2022-09-30 | 70.9 | -247.819 | -247.079 |
| 2022-06-30 | 71.811 | -241.74 | -247.652 |
| 2022-03-31 | 24.102 | -239.353 | -349.911 |
| 2021-12-31 | 20.34 | -220.522 | -340.141 |
| 2021-09-30 | 12.792 | -190.373 | -328.099 |
ATRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ATRA has a Quality Grade of C, ranking ahead of 37.13% of graded US stocks.
- ATRA's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
- HGEN, ARMP, and ZSAN are the stocks whose asset turnover ratios are most correlated with ATRA.
The table below shows ATRA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.025 | 1 | -1.135 |
| 2021-06-30 | 0.015 | 1 | -1.059 |
| 2021-03-31 | 0.007 | 1 | -0.973 |
| 2020-12-31 | 0.000 | NA | -1.036 |
| 2020-09-30 | 0.000 | NA | -1.093 |
| 2020-06-30 | 0.000 | NA | -1.152 |
ATRA Price Target
For more insight on analysts targets of ATRA, see our ATRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $33.38 | Average Broker Recommendation | 1.41 (Moderate Buy) |
Atara Biotherapeutics, Inc. (ATRA) Company Bio
Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. The company was founded in 2012 and is based in South San Francisco, California.
Latest ATRA News From Around the Web
Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To BeToday is shaping up negative for Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders, with the analysts delivering... |
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue EstimatesAtara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational ProgressTHOUSAND OAKS, Calif., May 08, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. |
The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues YetAtara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong... |
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)THOUSAND OAKS, Calif., May 05, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 6,250 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biot |
ATRA Price Returns
| 1-mo | -47.08% |
| 3-mo | -55.10% |
| 6-mo | -65.63% |
| 1-year | -70.04% |
| 3-year | -84.07% |
| 5-year | -96.86% |
| YTD | -53.05% |
| 2022 | -79.19% |
| 2021 | -19.71% |
| 2020 | 19.19% |
| 2019 | -52.59% |
| 2018 | 91.93% |
Loading social stream, please wait...